A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Fostamatinib With Respect to an Intravenous Micro Tracer Dose of [14C] R406 in Healthy Male Volunteers

Trial Profile

A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Fostamatinib With Respect to an Intravenous Micro Tracer Dose of [14C] R406 in Healthy Male Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2012

At a glance

  • Drugs Fostamatinib (Primary)
  • Indications B cell lymphoma; Rheumatoid arthritis; Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 21 Aug 2012 Last checked against ClinicalTrials.gov record.
    • 21 Aug 2012 Actual end date (August 2012) added as reported by ClinicalTrials.gov.
    • 01 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top